Phase 2 EVITA Trial Finds Exploratory Survival Signal With Daily Oral Vitamin C in CCUS and MDS

The EVITA phase 2 trial provides the first randomized evidence that correcting vitamin C deficiency in CCUS/MDS alters immune signaling and yields an exploratory survival benefit. The finding supports the cancer-interception strategy but requires confirmation in a larger phase 3 trial before clinical adoption. Epigenetic restoration via TET enzymes offers a plausible mechanism that warrants targeted follow-up studies.